The startup develops a healthy longevity platform that utilizes single-cell genomics and transcriptomics to provide aging diagnostics and therapeutic insights. By generating detailed diagnostic reports for clinics, the platform identifies potential drug repurposing candidates and enhances quality control in cell therapy.

The startup develops medical compounds and treatments that utilize real-time monitoring of animal activity and behavior to mitigate aging symptoms in pets and livestock. By enhancing health span and longevity, the company provides pet and cattle owners with effective solutions for maintaining their animals' vitality.

Asima Health develops a non-invasive, multi-cancer blood test for early detection of various cancers. This pan-genomic platform simultaneously screens for multiple malignancies from a single blood draw, offering an accessible alternative to current invasive screening methods. The technology aims to quickly rule out cancer or identify individuals requiring follow-up diagnostics like colonoscopy or mammography.

BE Therapeutics is engineering precursor tissue that mimics embryonic brain tissue to replace damaged neocortical and spinal cord tissue, facilitating normal maturation and integration post-transplantation. This technology aims to restore lost functions in individuals affected by stroke, trauma, neurodegeneration, and aging, addressing the current lack of effective treatments for central nervous system damage.

BrainKey utilizes advanced MRI analysis and genetic data interpretation to quantify brain health and provide personalized treatment recommendations. This approach addresses the challenge of identifying and managing brain health issues, enabling users to track changes over time and receive actionable insights for improved cognitive longevity.

Cleara is developing peptide-based therapeutics that selectively eliminate "scarred" senescent cells associated with chronic diseases and late-stage cancers, utilizing a proprietary platform technology to target specific cellular pathways. Their lead candidates, CL04177 and CL04183, demonstrate effective clearance of these cells in preclinical models, aiming to advance precision medicine for metastatic colon and triple-negative breast cancers.

The startup offers a healthcare platform that integrates patient relationship management and collaboration tools specifically for pediatricians and general practitioners. This technology enhances patient compliance and clinical outcomes by facilitating second opinions and follow-ups, while minimizing diagnostic errors in medical care delivery.

Cosmica Biosciences utilizes insights from space biology to accelerate drug discovery focused on longevity by studying the effects of low gravity on cellular aging. This approach aims to identify new biomarkers and therapeutic interventions that can enhance human health and lifespan on Earth.

Domina Therapeutics develops novel therapeutics for cognitive decline disorders including Alzheimer’s disease, bipolar disorder, and schizophrenia. The company utilizes a patentable, AI-assisted target discovery platform based on human brain neural network models derived from patient cells. This platform identifies compounds capable of restoring neural network function by targeting common underlying mechanisms across neurological conditions.

GenFlow Biosciences develops gene therapies utilizing the SIRT6 gene variant associated with centenarians to slow or reverse the aging process in humans and dogs. This approach aims to extend healthspan and lifespan, reducing healthcare costs and addressing the challenges of an aging population.

HealthyLongevity.cafe provides a personalized recipe platform that employs nutritional algorithms to generate customized meal plans focused on enhancing health and lifespan. The service offers science-based dietary guidance to individuals seeking to improve their well-being through tailored nutrition.

Healthy Longevity Clinic utilizes advanced diagnostic tools and personalized treatment protocols, including hormone replacement therapy and regenerative medicine, to lower biological age and enhance overall health. The clinic addresses age-related diseases and performance decline by providing tailored longevity programs that improve physical and cognitive function.

Juvena Therapeutics utilizes an AI-driven platform to identify and engineer secreted proteins into biologic therapeutics that restore tissue homeostasis. The company addresses the dysregulation of protein signaling that leads to degenerative diseases, including myopathies and metabolic disorders.

MaxWell Biosciences develops a synthetic immune system using its CLAROMER® platform, which creates small molecule compounds that mimic innate immune peptides to target a broad spectrum of pathogens. The technology addresses the decline of immune function associated with aging and aims to provide effective treatments for currently untreatable infectious diseases.

MitoRx Therapeutics develops first-in-class small molecule therapeutics that modulate mitochondrial metabolism to address cardiometabolic diseases, starting with obesity. Their platform utilizes targeted compounds to restore sulfide-signaling via enzymatic release within the mitochondria, reversing dysfunction. This approach aims to provide anti-obesogenic effects while preserving lean mass through adaptive metabolism restoration.

Lo provides a platform for managing and automating commercial real estate leasing workflows. It centralizes lease documentation, tracks key dates, and streamlines communication between landlords and tenants. This system helps commercial property managers reduce administrative overhead and ensure compliance across their portfolio.

The startup has developed a nanomedical platform that utilizes targeted nanoparticles to selectively remove disease-causing molecules from the bloodstream within minutes. This technology provides a new treatment option for major diseases, enhancing patient safety and efficacy compared to traditional methods.

Nightingale Health utilizes advanced biomarker analysis and ’omics technology to provide comprehensive health checks that identify chronic disease risks. By enabling early detection and personalized health insights, the company aims to enhance preventive healthcare and reduce health disparities.

This startup offers a healthcare drink supplement that combines nicotinamide riboside, magnesium, fisetin, and pterostilbene to enhance mental health and wellness. By improving DNA repair and reducing DNA damage, their products aim to extend lifespan and promote overall health.

Occuity develops handheld, non-contact optical instruments that utilize light reflection analysis to measure eye health and monitor chronic conditions such as diabetes and Alzheimer's disease. Their technology enables pain-free screening in non-clinical settings, improving accessibility and reducing costs for patients and healthcare providers.

Develops microbial training techniques to enhance healthspan and lifespan by optimizing the interactions between gut microbiota and host biology. This approach targets age-related decline and chronic diseases, offering potential improvements in metabolic health, immune function, and overall vitality.

Rejuvenation Technologies utilizes nucleoside-modified TERT mRNA to temporarily activate telomerase, enabling the safe extension of telomeres in human cells. This approach addresses the critical shortening of telomeres, which contributes to cellular aging and various age-related diseases, by potentially reversing the effects of aging at the chromosomal level.

Remedium Bio has developed the Prometheus™ adjustable gene therapy platform, which enables the localized delivery of therapeutic genes through a single subcutaneous injection, allowing for precise post-treatment dose adjustments. The company addresses significant clinical needs by providing durable alternatives to protein-based therapies for conditions such as obesity, type 2 diabetes, and osteoarthritis, potentially reducing treatment costs and improving patient outcomes.

Repair Biotechnologies develops a Cholesterol Degrading Platform that targets and reduces atherosclerotic plaque in arteries, a primary contributor to cardiovascular diseases such as heart attacks and strokes. This platform offers a tailored therapeutic approach to address conditions arising from excess cholesterol accumulation in various tissues.